Literature DB >> 25430081

Clonal origin and evolution of myelodysplastic syndrome analyzed by dysplastic morphology and fluorescence in situ hybridization.

Chun-Mei Fu1, Zi-Xing Chen, Dan-Dan Liu, Jun Zhang, Jin-Lan Pan, Jian-Ying Liang.   

Abstract

Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem/progenitor cells. As bone marrow cells are extremely diverse in these disorders, the origin and evolution of MDS clones are difficult to identify and trace. Cellular dysplasia is a distinct morphologic feature; however, whether the dysplastic cells represent abnormal clones or only nonspecific superficial phenomena remains to be clarified. To address this question, 97 patients were examined for dysplasia features, among them bone marrow slides of 16 patients with chromosomal abnormalities were subjected to fluorescence in situ hybridization (FISH) to determine the karyotype of these dysplastic cells. Furthermore, the emerging frequencies of abnormal karyotypes in various differentiated stages of each lineage were also evaluated by a combination of morphological evaluation and FISH karyotyping. Our results indicate that the overall percentage of dysplastic cells does not differ significantly among the WHO subtypes, while the megakaryoid lineage presents the most frequent dysplasia in all subtypes. A positive correlation between dysplastic cells and FISH-detectable abnormal clones was observed, but the dysplastic morphology was not a specific feature of FISH-detectable abnormal clones. FISH-detectable abnormal clones can differentiate into mature granulocytes and erythrocytes, in coexistence with cells originating from the normal clones.

Entities:  

Mesh:

Year:  2014        PMID: 25430081     DOI: 10.1007/s12185-014-1700-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  20 in total

Review 1.  Myelodysplastic syndromes.

Authors:  Ayalew Tefferi; James W Vardiman
Journal:  N Engl J Med       Date:  2009-11-05       Impact factor: 91.245

2.  Cytogenetic clonality analysis of megakaryocytes in myelodysplastic syndrome by dual-color fluorescence in situ hybridization and confocal laser scanning microscopy.

Authors:  K van Lom; A B Houtsmuller; W L van Putten; R M Slater; B Löwenberg
Journal:  Genes Chromosomes Cancer       Date:  1999-08       Impact factor: 5.006

3.  Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS).

Authors:  A Cantù Rajnoldi; S Fenu; G Kerndrup; E R van Wering; C M Niemeyer; I Baumann
Journal:  Ann Hematol       Date:  2005-04-19       Impact factor: 3.673

4.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.

Authors:  L Nilsson; I Astrand-Grundström; I Arvidsson; B Jacobsson; E Hellström-Lindberg; R Hast; S E Jacobsen
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

5.  Improvement of criteria for refractory cytopenia with multilineage dysplasia according to the WHO classification based on prognostic significance of morphological features in patients with refractory anemia according to the FAB classification.

Authors:  A Matsuda; U Germing; I Jinnai; M Iwanaga; M Misumi; A Kuendgen; C Strupp; Y Miyazaki; H Tsushima; M Sakai; M Bessho; N Gattermann; C Aul; M Tomonaga
Journal:  Leukemia       Date:  2007-02-01       Impact factor: 11.528

6.  Karyotypic identification of abnormal clones preceding morphological changes or occurring with no definite morphological features of myelodysplastic syndrome: a preliminary study.

Authors:  Jin-Yeong Han; Karl S Theil
Journal:  Lab Hematol       Date:  2007

7.  Fluorescence in situ hybridization for the study of cell lineage involvement in myelodysplastic syndromes with chromosome 5 anomalies.

Authors:  Kristina Anderson; Ingrid Arvidsson; Björn Jacobsson; Robert Hast
Journal:  Cancer Genet Cytogenet       Date:  2002-07-15

8.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

10.  Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31.

Authors:  A A N Giagounidis; U Germing; S Haase; B Hildebrandt; B Schlegelberger; C Schoch; L Wilkens; M Heinsch; H Willems; M Aivado; C Aul
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

View more
  1 in total

1.  Over-expression of miR-196b-5p is significantly associated with the progression of myelodysplastic syndrome.

Authors:  Jing Wen; Ying Huang; Hongying Li; Xupai Zhang; Peng Cheng; Donghong Deng; Zhigang Peng; Jun Luo; Weihua Zhao; Yongrong Lai; Zhenfang Liu
Journal:  Int J Hematol       Date:  2017-02-21       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.